Tag: brokerswatch

Sep 19
Gold futures settle lower to hold near their lowest level in over 2 years

Gold futures fell on Monday, giving back most of the climb in prices they saw on Friday, as investors await a Federal Reserve decision this week on interest rates. The central bank is widely expected to announce a rate hike of three-quarters of a point on Wednesday. December gold GCZ22, -0.07% fell $5.30, or 0.3%, […]

Sep 19
Kinross Gold stock surges on NYSE-leading volume after talks with Elliott lead to ‘enhanced’ buyback plan

Shares of Kinross Gold Corp. KGC, +9.73% shot up 7.9% in heavy volume in afternoon trading Monday, after the gold miner announced a new “enhanced” stock repurchase program, following “constructive discussions” with investor Elliott Investment Management LP. Trading volume ballooned to 29.1 million shares, making the stock the most actively traded on the NYSE. As […]

Sep 19
Vaccine stocks Pfizer, BioNTech, Moderna and Novavax slide after Biden says pandemic is over

Stocks of the three key vaccine makers fell sharply Monday, after President Joe Biden said the pandemic is over, in an interview with “60 Minutes” that aired on Sunday. Moderna Inc. MRNA, -8.98% fell 9.2%, Pfizer Inc. PFE, -1.79% was down 1.7% and its German partner BioNTech SE BNTX, -8.46% was down 8.4%. Novavax Inc. […]

Sep 19
Dow opens nearly 250 points lower as investors await Wednesday Fed decision

U.S. stocks opened lower on Monday, on track for a third day of declines, as investors await a decision from the Federal Reserve, which is expected to deliver another jumbo interest-rate hike on Wednesday. The S&P 500 SPX, -0.33% is down 31 points, or 0.8%, to 3,841. The Dow Jones Industrial Average DJIA, -0.24% retreated […]

Sep 19
UPDATE: Theravance Biopharma plans $250 million capital return program; stock jumps 3% premarket

Theravance Biopharma Inc. TBPH, +3.03% said Monday its board has authorized a $250 million capital return program, that includes buying back its own stock from GSK Plc GSK, -0.79%. The company will purchase GSK’s entire holdings of about 9.6 million shares at $9.75 a share with the closing expected Tuesday. The company also plans to […]

Sep 19
AutoZone stock gains after profit, sales rise above expectations as commercial business stays strong

Shares of AutoZone Inc. AZO, -2.11% rose 1.1% in premarket trading Monday, auto parts retailer reported fiscal fourth-quarter profit and sales that rose above expectations, helped by continued strength in its commercial business. Net income for the quarter to Aug. 27 rose to $810.0 million, or $40.51 a share, from $785.8 million, or $35.72 a […]

Sep 19
Canadian cannabis retailer High Tide raises debt to open more stores

High Tide Inc. HITI, -1.37% HITI, -1.52% a cannabis store operator and e-commerce company, said Monday it closed a five year, C$19 million ($14.3 million) senior secured credit facility with Alberta-based lender connectFirst Credit Union Ltd. The Calgary-based company plans to use the proceeds to increase its Canna Cabana discount cannabis store count to 150 […]

Sep 19
Granite Construction will no longer sell water resources, mineral services businesses, citing ‘market conditions’

Granite Construction Inc. GVA, +3.61% said Monday it no longer plans to sell its Water Resources and Mineral Services businesses, citing current market conditions. The construction materials company said the businesses’ assets will no longer be classified as held for sale, and the financial results will be reporting within continuing operations. “Although we saw significant […]

Sep 19
Ralph Lauren to return $2 billion to shareholders in the next three years

Ralph Lauren Corp. shares RL, +1.19% swung between gains and losses in premarket trade Monday, after the company outlined its strategic growth plan in a statement released ahead of an investor day in New York City. The clothing company said it expects to return about $2 billion in excess cash flow to shareholders through fiscal […]

Sep 19
Genelux sets IPO terms, as the biotech could be valued at up to $165 millino

Genelux Corp. GNLX, has set terms for its initial public offering, in which the California-based biotechnology company focused on treating difficult-to-treat tumors could be valued at up to $164.99 million. The company said it is offering 2.5 million shares in the IPO, which is expected to price between $6 and $7 a share, as the […]